Genentech

Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.

A meta-analysis based on genotyping data for more than 400,000 people with or without the disease led to 17 new risk loci mined for candidate genes

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

At the Personalized Medicine World Conference, stakeholders and the former FDA commissioner discussed how regulation can advance personalized medicine amid political uncertainty.

The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

Pages

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.